5 research outputs found
RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS
Optimalno zbrinjavanje oboljelih od malignih bolesti, ovisno o vrsti tumora, ukljuÄuje i odreÄivanje serumskih tumorskih biljega. Ti su biljezi heterogena skupina molekula Äija je koncentracija poviÅ”ena kod ljudi oboljelih od zloÄudnih tumora, ali se u niskim koncentracijama mogu naÄi i u plazmi zdravih pojedinaca. PoviÅ”ene koncentracije u plazmi nastaju zbog: promjena u samoj stanici, nekroze stanice te promjene izražaja ili izluÄivanja razliÄitih molekula. Kod nekih tumora same tumorske stanice mogu potaknuti druge stanice na luÄenje odreÄenih spojeva. U kliniÄkoj primjeni u ovom je trenutku izmeÄu ostalih dostupno odreÄivanje nekoliko serumskih tumorskih biljega: CEA, CA 19-9, CA 15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH i tiroglobulin. VeÄi broj serumskih tumorskih biljega primjenjuje se eksperimentalno i Äeka svoje mjesto u svakodnevnoj kliniÄkoj primjeni. Smjernice o primjeni tumorskih biljega Nacionalne akademije kliniÄke biokemije (National Academy of Clinical Biochemistry ā NACB) osmiÅ”ljene su da bi poticale prikladniju upotrebu testova tumorskih biljega od lijeÄnika primarne zaÅ”tite, kirurga, onkologa, ginekologa te ostalih specijalista koji se bave bolesniĀcima sa solidnim tumorima.Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners,
surgeons, oncologists, and other health care professionals giving care to patients with solid tumours
Racionalna primjena serumskih tumorskih biljega u dijagnostici i lijeÄenju solidnih tumora [Rational use of serum tumour markers in diagnostics and treatment of solidtumours]
Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners, surgeons, oncologists, and other health care professionals giving care to patients with solid tumours
Racionalna primjena serumskih tumorskih biljega u dijagnostici i lijeÄenju solidnih tumora [Rational use of serum tumour markers in diagnostics and treatment of solidtumours]
Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners, surgeons, oncologists, and other health care professionals giving care to patients with solid tumours
Recikliranje otpadnih brodova
Životni vijek veÄine brodova traje oko 20 ā 25 godina, nakon Äega se viÅ”e ne smatraju korisnim, te postaju otpad kojeg se na pravilan naÄin mora rijeÅ”iti. Svake godine se u reciklažna dvoriÅ”ta diljem svijeta Å”alje oko 4000 plovila. U Hrvatskoj, zbog jednostavnije izrade, zadovoljavajuÄe ÄvrstoÄe i relativno malih troÅ”kova održavanja, raste trend izgradnje plovila od stakloplastike. Takva plovila su vrlo postojana i dugotrajna i zbog tih razloga, nakon Å”to se prestanu upotrebljavati, ta plovila predstavljaju problem u zbrinjavanju otpada. Stakloplastika se može zbrinuti na tri naÄina, spaljivanjem u cilju dobivanja energije, odlaganjem na odlagaliÅ”ta otpada ili njenim recikliranjem i ponovnim koriÅ”tenjem. BuduÄnost stakloplastike se nalazi u njenom recikliranju, buduÄi da se ponovnim koriÅ”tenjem takvih materijala Å”tede vrijedni resursi i pridonosi se zaÅ”titi i oÄuvanju okoliÅ”a. TakoÄer, rjeÅ”ava se problem prenapuÄenosti starih plovila Å”to omoguÄuje izradu novih, Å”to doprinosi ravoju gospodarstva i turizma
RATIONAL USE OF SERUM TUMOUR MARKERS IN DIAGNOSTICS AND TREATMENT OF SOLID TUMOURS
Optimalno zbrinjavanje oboljelih od malignih bolesti, ovisno o vrsti tumora, ukljuÄuje i odreÄivanje serumskih tumorskih biljega. Ti su biljezi heterogena skupina molekula Äija je koncentracija poviÅ”ena kod ljudi oboljelih od zloÄudnih tumora, ali se u niskim koncentracijama mogu naÄi i u plazmi zdravih pojedinaca. PoviÅ”ene koncentracije u plazmi nastaju zbog: promjena u samoj stanici, nekroze stanice te promjene izražaja ili izluÄivanja razliÄitih molekula. Kod nekih tumora same tumorske stanice mogu potaknuti druge stanice na luÄenje odreÄenih spojeva. U kliniÄkoj primjeni u ovom je trenutku izmeÄu ostalih dostupno odreÄivanje nekoliko serumskih tumorskih biljega: CEA, CA 19-9, CA 15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH i tiroglobulin. VeÄi broj serumskih tumorskih biljega primjenjuje se eksperimentalno i Äeka svoje mjesto u svakodnevnoj kliniÄkoj primjeni. Smjernice o primjeni tumorskih biljega Nacionalne akademije kliniÄke biokemije (National Academy of Clinical Biochemistry ā NACB) osmiÅ”ljene su da bi poticale prikladniju upotrebu testova tumorskih biljega od lijeÄnika primarne zaÅ”tite, kirurga, onkologa, ginekologa te ostalih specijalista koji se bave bolesniĀcima sa solidnim tumorima.Optimal management of patients with solid tumors, depending on the tumour type, includes measurement of serum tumour markers levels. Serum tumour markers are heterogeneous molecules with concentrations elevated in persons with solid tumours, but could also be found in small amounts in plasma of healthy individuals. Elevated plasma concentrations are caused by cell changes, necrosis, changed expression or secretion of different molecules. In some tumour types tumour cells by themselves could stimulate other cells to secrete particular molecules. There are several serum tumour markers in the routine clinical praxis: CEA, CA 19-9, CA15-3, CA 125, CYFRA, NSE, PSA, HCG, AFP, LDH, thyreoglobulin. There are also several serum tumour markers in experimental use, waiting to be included into the routine clinical use. National Academy of Clinical Biochemistry (NACB) practice guidelines for use of tumour markers in clinical practice are designated to encourage more appropriate use of serum tumour marker tests by general medicine practitioners,
surgeons, oncologists, and other health care professionals giving care to patients with solid tumours